{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:12:30Z","timestamp":1791141150886,"version":"4.1.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"Importance<\/jats:title>Due to the often indolent nature of prostate cancer (PCA), treatment decisions must weigh the risks and benefits of cancer control with those of treatment-associated morbidities.<\/jats:p><\/jats:sec>Objective<\/jats:title>To characterize long-term treatment-related adverse effects and complications in patients treated for PCA compared to a general population of older males.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study used a novel approach linking data from 2 large PCA prevention clinical trials (the Prostate Cancer Prevention Trial and the Selenium and Vitamin-E Cancer Prevention Trial) with Medicare claims records. This analysis included patients with PCA who had been treated with prostatectomy or radiotherapy compared with an untreated control group. Multivariable Cox regression was used, with a time-varying covariate for the occurrence of PCA treatment, adjusted for age, race, and year of time-at-risk initiation, and stratified by study and intervention arm. Data analyses were performed from September 21, 2022, to March 18, 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>Prostatectomy and radiotherapy occurring after a PCA diagnosis, identified from trial data or Medicare claims records.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Ten potential PCA treatment-related complications identified from Medicare claims data.<\/jats:p><\/jats:sec>Results<\/jats:title>The study sample comprised 29\u202f196 participants (mean [SD] age at time-at-risk initiation, 68.7 [4.8] years). Of these, 3946 participants had PCA, among whom 655 were treated with prostatectomy and 1056 with radiotherapy. The 12-year hazard risk of urinary or sexual complications was 7.23 times greater for those with prostatectomy (95% CI, 5.96-8.78; P <\/jats:italic>&amp;lt;\u2009.001) and 2.76 times greater for radiotherapy (95% CI, 2.26-3.37; P <\/jats:italic>&amp;lt;\u2009.001) compared to untreated participants. Moreover, among participants treated with radiotherapy, there was a nearly 3-fold greater hazard risk of bladder cancer than in the untreated (hazard ratio [HR], 2.78; 95% CI, 1.92-4.02; P <\/jats:italic>&amp;lt;\u2009.001), as well as an approximately 100-fold increased hazard risk of radiation-specific outcomes including radiation cystitis (HR, 131.47; 95% CI, 52.48-329.35; P <\/jats:italic>&amp;lt;\u2009.001) and radiation proctitis (HR, 87.91; 95% CI, 48.12-160.61; P <\/jats:italic>&amp;lt;\u2009.001). The incidence per 1000 person-years of any 1 of the 10 treatment-related complications was 124.26 for prostatectomy, 62.15 for radiotherapy, and 23.61 for untreated participants.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study found that, even after accounting for age-related symptoms and disease, PCA treatment was associated with higher rates of complications in the 12 years after treatment. Given the uncertain benefit of PCA treatment for most patients, these findings highlight the importance of patient counseling before PCA screening and treatment and provide a rationale for pursuing opportunities for cancer prevention.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2024.4397","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T16:31:50Z","timestamp":1730997110000},"page":"1654","source":"Crossref","is-referenced-by-count":42,"title":["Long-Term Adverse Effects and Complications After Prostate Cancer Treatment"],"prefix":"10.1001","volume":"10","author":[{"given":"Joseph M.","family":"Unger","sequence":"first","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathee","family":"Till","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Tangen","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis J.","family":"Goodman","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Barlow","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riha","family":"Vaidya","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori M.","family":"Minasian","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, US National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard L.","family":"Parnes","sequence":"additional","affiliation":[{"name":"Division of Cancer Prevention, US National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Ian M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"CHRISTUS Santa Rosa Health System and The University of Texas Health Science Center at San Antonio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"coi240059r1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ijc.29538","article-title":"Prevalence of incidental prostate cancer: a systematic review of autopsy studies.","volume":"137","author":"Bell","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"coi240059r2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"coi240059r3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement.","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"13","key":"coi240059r4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial.","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"coi240059r5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1113135","article-title":"Prostate-cancer mortality at 11 years of follow-up.","volume":"366","author":"Schr\u00f6der","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"coi240059r6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/0197-2456(94)00XXX-M","article-title":"Design of the Prostate Cancer Prevention Trial (PCPT).","volume":"16","author":"Feigl","year":"1995","journal-title":"Control Clin Trials"},{"issue":"3","key":"coi240059r7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer.","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"coi240059r8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).","volume":"301","author":"Lippman","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"coi240059r9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jnci\/djy035","article-title":"Using Medicare claims to examine long-term prostate cancer risk of finasteride in the Prostate Cancer Prevention Trial.","volume":"110","author":"Unger","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"coi240059r10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"3","key":"coi240059r12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2307\/2532096","article-title":"The Cox proportional hazards model with change point: an epidemiologic application.","volume":"46","author":"Liang","year":"1990","journal-title":"Biometrics"},{"issue":"11","key":"coi240059r13","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jama.2017.1704","article-title":"Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years.","volume":"317","author":"Barocas","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"coi240059r14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0090-4295(00)00539-2","article-title":"Complications after radical retropubic prostatectomy in the Medicare population.","volume":"56","author":"Benoit","year":"2000","journal-title":"Urology"},{"issue":"33","key":"coi240059r15","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.1200\/JCO.2006.07.9954","article-title":"Patient and treatment factors associated with complications after prostate brachytherapy.","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi240059r16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.juro.2007.03.126","article-title":"Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.","volume":"178","author":"Elliott","year":"2007","journal-title":"J Urol"},{"issue":"19","key":"coi240059r17","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1093\/jnci\/92.19.1582","article-title":"Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.","volume":"92","author":"Potosky","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"coi240059r18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/jama.283.3.354","article-title":"Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.","volume":"283","author":"Stanford","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"coi240059r19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.6004\/jnccn.2015.0009","article-title":"Cost implications and complications of overtreatment of low-risk prostate cancer in the United States.","volume":"13","author":"Aizer","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"4 Pt 1","key":"coi240059r20","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.juro.2007.05.135","article-title":"Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.","volume":"178","author":"Krupski","year":"2007","journal-title":"J Urol"},{"issue":"12","key":"coi240059r21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMp1811521","article-title":"Contingent knowledge and looping effects: a 66-year-old man with PSA-detected prostate cancer and regrets.","volume":"381","author":"Aronowitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"coi240059r22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jama.2023.26491","article-title":"Functional outcomes after localized prostate cancer treatment.","volume":"331","author":"Al Hussein Al Awamlh","year":"2024","journal-title":"JAMA"},{"issue":"20","key":"coi240059r23","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/jnci\/dji313","article-title":"30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity.","volume":"97","author":"Alibhai","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"coi240059r24","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/j.ijrobp.2011.02.006","article-title":"Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer.","volume":"81","author":"Bekelman","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"coi240059r25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.juro.2010.03.031","article-title":"Impact of prior prostate radiation on complications after radical prostatectomy.","volume":"184","author":"Gotto","year":"2010","journal-title":"J Urol"},{"issue":"14","key":"coi240059r26","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2009.1451","article-title":"Comparative effectiveness of minimally invasive vs open radical prostatectomy.","volume":"302","author":"Hu","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"coi240059r27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.eururo.2011.05.052","article-title":"Late gastrointestinal toxicities following radiation therapy for prostate cancer.","volume":"60","author":"Kim","year":"2011","journal-title":"Eur Urol"},{"issue":"6 Pt 1","key":"coi240059r28","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1097\/01.ju.0000145222.94455.73","article-title":"Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies.","volume":"172","author":"Kundu","year":"2004","journal-title":"J Urol"},{"issue":"5","key":"coi240059r29","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0022-5347(05)65662-5","article-title":"Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases.","volume":"166","author":"Lepor","year":"2001","journal-title":"J Urol"},{"key":"coi240059r30","first-page":"379","article-title":"Morbidity of contemporary radical retropubic prostatectomy for localized prostate cancer.","volume":"9","author":"Lerner","year":"1995","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"coi240059r31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer.","volume":"368","author":"Resnick","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"coi240059r32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0360-3016(96)00468-3","article-title":"Late GI and GU complications in the treatment of prostate cancer.","volume":"37","author":"Schultheiss","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"coi240059r33","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1001\/jama.2012.460","article-title":"Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.","volume":"307","author":"Sheets","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"coi240059r34","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrurol.2010.23","article-title":"Management of radiation cystitis.","volume":"7","author":"Smit","year":"2010","journal-title":"Nat Rev Urol"},{"key":"coi240059r35","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/917941","article-title":"Radiation proctitis: current strategies in management.","volume":"2011","author":"Do","year":"2011","journal-title":"Gastroenterol Res Pract"},{"issue":"8","key":"coi240059r36","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1600::AID-CNCR24>3.0.CO;2-0","article-title":"Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma.","volume":"79","author":"Neugut","year":"1997","journal-title":"Cancer"},{"issue":"5","key":"coi240059r37","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.juro.2008.07.038","article-title":"Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.","volume":"180","author":"Nieder","year":"2008","journal-title":"J Urol"},{"issue":"2","key":"coi240059r38","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V","article-title":"Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery.","volume":"88","author":"Brenner","year":"2000","journal-title":"Cancer"},{"key":"coi240059r39","doi-asserted-by":"crossref","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"coi240059r40","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.152822","article-title":"Clinical and pathological characteristics of bladder cancer in post brachytherapy patients.","volume":"216","author":"Au","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"5","key":"coi240059r41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00345-016-1934-z","article-title":"Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality.","volume":"35","author":"Keehn","year":"2017","journal-title":"World J Urol"},{"key":"coi240059r11","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch","year":"2011"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2826069\/jamaoncology_unger_2024_oi_240059_1734561022.80916.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:02:04Z","timestamp":1734624124000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2826069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2024.4397","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}